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Abstract
Summary A personalized patient education tool for decision
making (PET) for postmenopausal women with osteoporosis
was developed by means of a systematic development ap-
proach. A prototype was constructed and refined by involving
various professionals and patients. Professionals and patients
expressed a positive attitude towards the use of the PET.
Introduction The purpose was to systematically develop a
paper-based personalized PET to assist postmenopausal wom-
en with osteoporosis in selecting a treatment in line with their
personal values and preferences.
Methods The development of the PETwas based on a system-
atic process including scope, design, development of a proto-
type, and alpha testing among professionals and patients by
semi-structured interviews.
Results The design and development resulted in a four-page
PET prototype together with a one-page fact sheet of the dif-
ferent drug options. The prototype PET provided the personal
risk factors, the estimated individualized risk for a future
major osteoporotic fracture and potential reduction with
drugs, and a summary of advantages and disadvantages
whether or not to start drugs. The drug fact sheet presents five
attributes of seven drugs in a tabular format. The alpha testing
with professionals resulted in some adaptations, e.g., inclusion
of the possibility to calculate fracture risk based on various
individual risk scoring methods. Important results from the
alpha testing with patients were differences in the fracture risk
percentage which was seen as worthwhile to start drugs, the
importance of an overview of side effects, and of the timing of
the PET into the patient pathway. All women indicated that the
PET could be helpful for their decision to select a treatment.
Conclusion Physicians and patients expressed a positive atti-
tude towards the use of the proposed PET. Further research
would be needed to test the effects of the PETon feasibility in
clinical workflow and on patient outcomes.
Keywords Decision aid . Osteoporosis . Patient . Patient
educational tool . Shared decisionmaking
Introduction
There is robust evidence that drugs reduce the risk of os-
teoporotic fracture in postmenopausal women with
established osteoporosis [1–3]. However, treatment non-
adherence limits the (cost)-effectiveness of osteoporosis
treatment in postmenopausal osteoporosis women that
have been prescribed preventive drugs appropriately [4].
Poor uptake rates or poor adherence to therapy may be due
to unaddressed patient values and preferences [5–7].
A way to facilitate patient understanding and to elicit
patient preferences is the use of a patient education tool
for decision making (PET) (or patient decision aid
(PDA)) during the consultation [5]. A PDA is an
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evidence-based information tool that describes the avail-
able treatment options and their salient attributes and
that also includes a value elicitation method and thereby
can facilitate shared decision making [5, 8, 9]. A PET
refers to a tool that does not include a value elicitation
method. PET/PDAs are designed to support patients to
make decisions when there is more than one reasonable
option and when patients’ personal preferences are rel-
evant and important given the tradeoff between pros and
cons of a single option [10]. Shared decision making—
clinicians and patients making decisions together using
the best available evidence—is more likely if the deci-
sion support tools have been developed for use in face
to face clinical encounters [11]. PET/PDAs have been
found to significantly improve patients’ knowledge
about the available options and to reduce decisional
conflict. There is a variable effect of PET/PDAs on
treatment choices including the uptake of medication
[9]. The effects of PET/PDAs on adherence with the
chosen option are inconclusive although there are some
indications that PET/PDAs may increase patients’ adher-
ence to the treatment option of first choice [9, 11, 12].
A PET was previously developed and tested for the
decision to start or not an oral bisphosphonate therapy
in at-risk women with osteoporosis [5]. The PET was
shown to improve the quality of clinical decisions of
bisphosphonate therapy and improved the proportion of
patients with high adherence level [5]. In recent years,
new medications have however been introduced to treat
osteoporosis which requires the development of a PDA
that incorporates all possible medications. In addition,
the assessment of personalized estimation of the risk
of future major fracture [13] has become available.
Recently, we also conducted qualitative and quantitative
studies to get insights into the preferences of patients
towards medication attributes [14, 15].
The aim of the current study was therefore to develop a
new personalized PET for postmenopausal women with oste-
oporosis for use in face to face clinical encounters that assists
individual patients who are considering options for drug treat-
ment to prevent fractures in selecting a treatment that is in line
with their personal values and preferences. To make PETs
acceptable for the main stakeholders (patients and clinicians)
and feasible for use in practice, a systematic approach for
development with strong input from both patients and clini-
cians is recommended [16]. In this paper, we report about the
findings and conclusions in the different steps of the develop-
mental process.
Methods
Elements of the patient decision aid development process as
described by Coulter et al. were followed, until the beta testing
phase [16]. The key elements are shown in Fig. 1.
Scope
The project group discussed the exact scope of the PET in-
cluding the target group, the type of decisions addressed, and
the setting in which the decision aid would be used.
Design
The International Patient Decision Aid Standards (IPDAS)
Collaboration describes criteria and minimum standards to
assess the quality of PDAs, i.e., the quality of the development
process and shared decision making design elements [17, 18].
The six Bqualifying^ criteria that a tool should meet to be
considered a PDA were included. Five items were about in-
formation dimension (providing information about options in
sufficient detail to make a specific decision), and one item
about values dimension (clarifying and expressing values).
The items from the information dimension are as follows:
the tool describes the health condition or problem for which
the decision is required, the tool explicitly states the decision
that needs to be considered, the tool describes the options
available for the decision, the tool describes the positive fea-
tures of each option, and the tool describes the negative fea-
tures of each option. The item from the values dimension is as
follows: the tool describes what it is like to experience the
consequences of the options (e.g., physical, psychological,
social) [17]. As we did not incorporate a value elicitation
method, our tool is better named as a PET.
The clinical content and the format of our PETwere based
on evidence-based European and Dutch guidelines for the
diagnosis and management of osteoporosis, literature about
the assessment of individual fracture risk, guidelines for pa-
tients decision aids and short decision support tools for pa-
tients, literature about shared decision making and effective
risk communication, previous qualitative and quantitative
work about patients’ preferences for osteoporosis drug treat-
ment, and existing osteoporosis PETs.
Prototype development
The prototype was developed in an iterative process by the
project team based on the information gathered in the design
Scoping  Design  
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Fig. 1 Development model of
our PET until alpha testing, based
on Coulter et al. [12]
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phase and previous studies including focus group [15] and a
discrete-choice experiment [14].
Alpha testing with professionals
The prototype was refined in an iterative process involving
various professionals including researchers, clinicians, and
medical nurses. Eligible professionals were selected by the
project team. Semi-structured face to face interviews were
conducted to assess the acceptability and usability of the con-
tent and the format. We aimed for a minimum of five inter-
views. The interviews were audiotaped, and field notes were
made during all the interviews. Afterwards, the interviews
were listened to several times and compared and combined
with the field notes. Quotations and comments of the patients
were placed and summarized around the main elements of the
prototype. The results from the interviews were discussed
among the project group. Only one researcher (GH) per-
formed the analyses, but this is a person without any conflict
of interest in this field. It is an external researcher from an
independent research group.
Alpha testing with patients
Semi-structured interviews were then conducted with outpa-
tients to assess the comprehensibility and usability of the con-
tent and the format of the prototype. Eligible subjects (women
with or at risk of osteoporosis) were recruited during their visit
to the polyclinic by the physician or medical nurse. We aim to
interview at least five subjects. The patients were confronted
with the elements of the prototype PET and asked for their
comments by asking questions and follow-up probes. The
interviews were audiotaped, and field notes were made during
interviews. The comments of the patients were summarized
around the main elements of the prototype of the PET, using
the method described above.
Results
Scope
The scope of the PETwas to assist in clinical setting postmen-
opausal women in their decision to start anti-osteoporotic
drugs in addition to life style changes and to help them in
choosing the drug they preferred. There are two hierarchical
steps to be distinguished within this decision: (1) Am I going
to start drug treatment (Yes/No)? and if Yes, (2) Which drug
do I prefer?
It was decided to develop a paper-based PET for use during
the face to face clinical encounter in the polyclinic. Although
web-based stand-alone decision aids are also developed that
are meant to be used by patients independently in advance of
the decision making consultation with the clinician, it was
decided to develop a short paper-based PET as the clinicians
feel the need to facilitate shared decision making with patients
during the patient contacts. The advantage of using short de-
cision support tools (minimal interventions) in clinical en-
counters is that they can facilitate patient involvement without
substantially increasing consultation length [5, 19, 20].
Design phase
Patients’ views
The focus groups that were conducted to identify important
osteoporosis medication attributes for patients showed that the
most important attributes were effectiveness, side effects, and
frequency and mode of administration [15]. The discrete-
choice experiment on treatment preferences for osteoporosis
drugs revealed that patients prefer higher efficacy, lower costs,
and less frequent dosing regimens. They preferred 6-month
subcutaneous injection and oral monthly tablet, and disliked
gastro-intestinal disorders more than other common side ef-
fects. It is noteworthy that preferences for treatment attributes
varied significantly between patients [14], which justifies the
development of a patient PET that facilitates individual deci-
sion making. In another study, it was found that the most
common reasons expressed against bisphosphonate therapy
were concerns about side effects or distrust of medications
in general [7]. We included these findings in our PET.
Literature review and consequences for the development
of the PET
TheEuropean andDutch clinical practice recommendations pro-
vided guidance for identification of persons at risk and for man-
agement of postmenopausal osteoporosis.Recommendations for
drug treatment are developed following GRADE guidelines [2,
21]. Although the fracture risk assessment tool (FRAX) is not
standardly recommended for person with a recent fracture in the
Netherlands [21], it might be assumed that patients will become
more motivated to treatment adherence after being given a per-
sonal absolute risk score on developing a fracture in the next
10 years, by use of the FRAX-score, and that shared decision
making about treatment will be facilitated. An estimated fracture
risk is more important for patients than the more technical lan-
guageof bonemineral density (T-scores). Literature suggests that
patients appreciate graphical information about their risk of a
certain disease and graphical informationwithin a certain limited
time frame is preferred above textual risk communication [22,
23]. Natural frequencies visualized by a population diagram ap-
pear to be an appropriate method to explain to patients their indi-
vidual risk [23].We thereforedecided to include theFRAX-score
for individual fracture risk assessment in our PET.
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After accounting additionally for current national recom-
mendations and availability of reimbursement of specific
drugs in the Netherlands, Balendronate^ and Brisedronate^
were included as first choice drugs in our PET, and
Bdenosumab,^ Bzoledronic acid,^ Bstrontium ranelate,^
Braloxifene,^ and Bibandronate^ as second choice drugs.
Based on the overviews of the anti-fracture efficacy of these
medicines for postmenopausal women with a high fracture
risk, we communicated a mean risk reduction of 50 % for
future major osteoporotic fractures (clinical spine, forearm,
hip, or shoulder fracture) independent of the specific drug.
First prototype
Two examples of decision aids in postmenopausal osteoporo-
sis that match our purpose were found. For the decision
whether or not to start drug treatment, the Osteoporosis
Choice PET was developed at the Mayo Clinic in the US
(http://shareddecisions.mayoclinic.org/decision-aids-for-
chronic-disease/other-decision-aids/) and conveys the pros
and cons of treatment using an estimate of the patient’s risk
of bone fracture. For the second decision BWhich drug do I
prefer?,^ the so-called Option Grids (www.optiongrid.co.uk)
matched with our purposes. An Option Grid is a one-page
summary that provides answers to patients’ frequently asked
questions about specific attributes (characteristics) of the
drugs organized in a tabular form. The specific features for
each of the possible drug options are presented across the table
columns [24]. As indicated above, in our case, the features or
attributes of the available osteoporosis drugs (the options)
were derived from previous qualitative and quantitative stud-
ies [14, 15]. We used the above mentioned tools as well as the
Dutch web-based stand-alone PET osteoporosis (http://
keuzehulpen. thuisar ts .nl /keuzehulp-osteoporose-
botontkalking-voorkomen-van-botbreuken), which was
developed in parallel with the Dutch guidelines [21], for the
development of our PET.
The results of the design phase resulted in the first proto-
type: a four-page PET together with a one-page fact sheet. The
main elements of both are shown in Table 1.
Alpha testing with professionals
Two clinicians, two researchers, and two rheumatology spe-
cialist nurses were interviewed. The nurses indicated that the
current consultation in the osteoporosis polyclinic is already
extensive and comprehensive and that the PET should have
proven added value to be acceptable in daily practice.
The most important comment concerning the content of the
PET was about the fracture risk score and the time frame
(within 3 years or 5 years instead of 10 years) that should be
used to calculate the risk score of our target group adequately.
Especially for patients with recurrent fractures and falls,
FRAXmay underestimate the fracture risk. Two other models
were mentioned by the clinicians and one researcher: the
Garvan fracture risk calculator (GARVAN-FRC) (http://
www.garvan.org.au/bone-fracture-risk) and a nomogram
developed by van Geel et al. [25]. They could be especially
useful after a recent fracture.
One researcher had doubts about the applicability of a fact
sheet in the Netherlands because it is meant in situations were
shared decision making already takes place, and in the
Netherlands, this might not yet be the case. This would imply
that patients may be confronted with a fact sheet that presents
a menu for anti-osteoporotic drugs that are in fact not on the
menu of the prescribing clinician who is following his or her
own routines or that of the team or institution where he or she
is appointed.
Second prototype
As a result of these interviews, we included in the PET the
possibility to calculate various risk scores with 10-year and 5-





– A patient’s individualized fracture risk (%) within the next 10 years
based on the FRAX
Page 2
– An explanation of the natural course, the individualized risk
percentage without drugs in natural frequencies and visualized by a
population diagram
Page 3
– An explanation of the individualized risk percentage with drugs in
natural frequencies and visualized by a population diagram
Page 4
–A summary of the choices (drug treatment or not) with their
advantages and disadvantages
– Some words about the importance of a healthy lifestyle regardless of
the choice
– Some considerations about individual preferences for certain drugs
Fact sheet
Presentation of seven drugs (options) that can help to prevent osteoporotic
fractures with their attributes
–Which bones are predominantly protected?
–What is the mode of administration?
–What is the frequency of administration?
–How do you have to take the pill or powder or place of administration
of injection or infusion?
–What are the side effects?*
*Instead of presenting side effects for each drug, the advice is to talk with
the physician or medical nurse about the possible side effects of the
various drugs
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year risk prediction (FRAX, GARVAN-FRC, and the nomo-
gram developed by Van Geel et al. [1]) dependent on the
answers of the patients on the questions about risk factors,
more specifically about recent fractures and falls. Moreover,
we made a PET version with only a description of risk factors
and the possibility to give an estimate of the fracture risk and
the time frame as estimated by the clinician (the last prototype
written in English is included in Appendix 1 (decision aid) and
2 (option grid)).
Alpha testing with patients or persons at risk
for osteoporosis
Six females were interviewed, and the duration of each inter-
viewwas between 12 and 28min. Five women were postmen-
opausal, aged 55 to 80 years, having either a prior fracture or a
diagnosis of osteoporosis. Three women received osteoporotic
drugs.We tested the content and format of the prototype main-
ly on comprehensibility and ability to help patients with deci-
sion making. We did not calculate a real individual fracture
risk score but we used instead a fictitious number and a 10-
year timeframe.
The content and format of the four-page PETwere discussed.
First, subjects had to indicate whether they understood the per-
centages of the fracture risk and the risk reduction by visualizing
the natural frequencies in a population diagram. All women
indicated that the explanation of the risk rate illustrated by the
Bpuppets^ of the population diagram was clear for them.
BA graph or schematic diagram is always more clear
than just a number or only narratively.^
All women indicated that it could be helpful for their deci-
sion to take or not to take drugs. However, there were differ-
ences in the fracture risk percentage which was seen as worth-
while to start drugs. Women who have experience with (the
consequences of) fractures themselves or in their surrounding
were more willing to take drugs, regardless of their fracture
risk.
BMy risk score should at least be 50 %.^
BOnly if my chance to break a bone becomes 0 %, I
would take medicines, they harm your body always
somewhere.^
BA risk of 30 % is well worth the effort to take medi-
cines for me, considering my age, imagine that you
break a bone. I have a friend who has broken a bone
and I will do all that I can to prevent that.^
BIf you know the consequences of breaking a bone, you
surely want a pill.^
BI believe it is good to take medicines in my situation
and I will see what happens.^
BSide effects are the most important for me. So I first
need to know the side effects.^
Subsequently, the content and format of the fact sheet, pre-
senting the attributes of the seven drugs (options), were
discussed. The women indicated that the information was
clear but that the format could be improved, e.g., the text size
should increase to improve the readability.
The overview of the different drugs with their attributes
was seen as an Beye opener,^ and women indicated that it
surely could be helpful to choose a drug. They indicated that
an overview of the most important or common side effects
was important for them.
BYes, but side effects are most important for me, so I
first need to know the side effects. After that, I would
choose for a drug that fits in my way of life, in my daily
routine.^
BYes, it could be helpful. I don’t like injections but even-
tually I would choose an injection because it is only 2
times a year.^
BYes, a tablet once a day you can easily forget, you have
always to remember it, I would choose for a tablet once
a month and mark it on the calendar (the first of each
month). And I prefer a drug that is effective for all
bones.^
BYes, it surely can help to choose a drug that fits to my
daily life. I am not in a hurry in the morning but if you
are (children and/or job), you probably will choose for
an injection. A choice that fits better in your life can
make it easier to continue.^
BYes, surely helpful to make a conscious choice. What
effort you have to take for it, is an important issue. The
various possibilities (and once a day, week, months)
give you a better overview than just a tablet. Side effects
are also important for me. I would like to know the most
important ones, so that I know that if I have side effects,
they might come from the drugs.^
Finally, the introduction or timing of the fact sheet into the
patient pathway maybe important for its usefulness, i.e., for
some patients the first consultation in the polyclinic might be
too early.
BTomake a choice during this first consultation could be
too much. I might already be surprised by the fact that I
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need drugs and by the technical terms. I think it might be
better to present the options for drugs at a later time, e.g.
at the family physician’s office.^
BI like the idea to have the possibility to switch my drug
if it turns out that I have problems with the first one, that
I have a choice, and that I can have an overview of the
various possibilities. The table could therefore also be
useful later on in the process.^
Discussion
Summary
The development of our PET was based on a systematic de-
velopment process that includes scoping, design, development
of a prototype, and alpha testing with professionals and pa-
tients in an iterative process [16]. The content and format of
the PET were based on a literature study including clinical
guidelines, assessments of individual fracture risk, guidelines
for PET/PDAs, shared decision making, risk communication,
examples of other PETs, and studies about patients’ prefer-
ences for osteoporosis drug treatment. Alpha testing with pa-
tients revealed that they all expressed a positive attitude to-
wards the use of the PET.
This resulted in a four-page PET together with a one-page
fact sheet. The PET provides the patient’s individualized risk
of having a major osteoporotic fracture based on absence or
presence of risk factors (page 1), an explanation of the esti-
mated risk (page 2), an explanation of the reduction of the
fracture risk with drugs (page 3), advantages and disadvan-
tages of the option Bdrugs^ and the option Bdoing nothing,^
and some considerations about possible preferences for certain
drugs (page 4). In the fact sheet, five attributes of seven drugs
are presented in tabular form.
Weak and strong points
A potential limitation of our PET is that we did not develop all
parts of PDAs that are prescribed by the IPDAS criteria as the
tool will be integrated in a face to face consultation and is not
to be used as stand-alone tool by the patient. The values di-
mension criteria—a PDA describes what it is like to experi-
ence the consequences of the options (e.g., physical, psycho-
logical, social)—is not fully elaborated in the tool itself, and
this explains why we prefer named our tool as a PET. It is
therefore important that during the consultation the clinician
or the medical nurse stimulates the patient to make his own
choice by thinking about the physical, psychological, and/or
social consequences of the various options, for example: Can
you imagine what breaking a bone means to you? Would it be
a problem for you to follow the instructions for the intake of
this specific drug?
An overview of the side effects of the drugs in the format of
a summary in the fact sheet turned out to be more complicated
than initially expected. Accurate interpretation of the risk of
side effects is difficult because of various sources of informa-
tion (e.g., randomized controlled trials versus case reports)
that provide varying levels of evidence [26]. Moreover, the
question was raised whether only the common side effects
should be mentioned or also the serious but usually very rare
side effects. The best way to communicate risk of side effects
to patients would also need to be further investigated. This is
an important issue for debate as the alpha testing with patients
revealed that a summarized overview of the most common
side effects is viewed as highly important to them.
Therefore, it will be necessary to provide this information in
the fact sheet. Experts on this field but also end users (patients)
should be involved in such process. A recently updated review
about the benefits and harms of pharmacologic osteoporosis
treatments might also be helpful for that purpose although not
all the drugs included in our fact sheet are included in the
review [26]. Another potential weakness is that, although we
recommend the patient to discuss non-pharmacological op-
tions (such as physical activity or nutrition) with doctors, our
PET focused mainly on pharmacological options, and we
therefore did not include an option grid for all possible non-
pharmacological options. An integrated PET that would in-
clude both pharmacological and non-pharmacological options
would be interesting.
Although the alpha testing phase yielded useful infor-
mation for the further development of our PET, it should
be mentioned that a relatively low number of professionals
and patients were involved in this phase and that the pa-
tients were recruited from only one hospital. We can there-
fore not assure that the broad perspective of all potential
users was captured. Before implementation of the tool at a
large scale, it would be important to further test it in a
larger and more representative group of patients with os-
teoporosis, the so-called beta testing of the tool. In addi-
tion, high-quality qualitative research (including assess-
ment by two researchers) would be needed in further as-
sessments of the tool and to investigate the most frequent-
ly asked questions and preferences of patients.
A close link between clinical practice guidelines and the
content of PETs through collaborative development is impor-
tant and can facilitate the implementation of PETs in clinical
practice [16]. The clinical content of our PET was based on
evidence-based Dutch and European guidelines, but a formal
relation with the (Dutch) guideline shall be established when
the tool will be tested in real practice. Another advantage of
the current decision aid is the possibility to flexibly use differ-
ent available risk score, improving the possibility to provide
adequate individual risks.
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Recommendations and considerations for further
development, research, and implementation
Besides the possible solutions for the weak points of the pro-
totypes, i.e., stimulating the patient to make his or her own
choice by helping the patient imagine what it is like to expe-
rience the effects of the options, and providing a summarized
overview of the side effects, there are several other issues that
need attention.
The discussion and research about the most appropriate
fracture risk assessment tool, especially for patients with
recurrent fractures and falls, is ongoing and may have
consequences for the assessment of an individual risk
score in our PET depending on the target group of the
PET [25, 27, 28].
With regard to the choice of drugs by patients, there are
differences between the Dutch and European guidelines
[2, 21]. The Dutch guidelines are more restricted with
first- and second-line treatment options, and this may
have consequences for the applicability of PET outside
the Netherlands.
The lay-out of the fact sheet needs further improvement.
Although a fact sheet is normally limited to one side of stan-
dard size paper and the information is purposefully limited
[19], it will be a challenge to include the required information,
including common side effects, in a more attractive and read-
able format.
The next step in the development process of the PET
including the fact sheet is field or beta testing with
patients and professionals in different settings. Field
testing in Breal world settings^ is important to assess
the feasibility of both tools, and feasibility is essential for
implementation.
Many factors have been identified that might enable or
prevent successful implementation of interventions in
healthcare professional practice [29]. It is beyond the scope
of this paper to discuss them all. Some factors important for
future implementation came up in our study up to now. As
mentioned before, a close link between guidelines and PETs is
important and can facilitate the implementation of the PETs in
clinical practice. The professionals who have to work with the
tools need to be convinced of the added value of the PETs
compared to their current procedures. Working with these
tools has to fit in their daily routine or they have to be con-
vinced that changing their daily routine would be efficacious.
In a recent review, it was found that professional indifference,
stemming from lack of confidence in the content of the PET/
PDAs and concern about disruption to established workflows,
was an important barrier of implementation [30]. Another im-
portant issue that came up in our study is that patients need to
be sensitive for the information at the moment of providing
the information. Therefore, the timing of introduction of the
tools into the patient pathway needs to be considered carefully.
Whether the use of the PET including the fact sheet will
stimulate uptake rates or adherence rates for drug treatment is
unknown. Montori et al. found a weak effect of an osteoporo-
sis choice PET on medication adherence [5]. Research on the
effects of PET/PDAs on medication uptake or treatment ad-
herence concerning various conditions shows mixed or incon-
clusive results [9, 11, 12]. Our interviews with patients show
that patient’s thoughts about what risk and subsequently what
fracture risk reduction is worth the effort to start drug treat-
ment were quite diverging. In a study of patients’ expectation
of benefit from preventive drugs, it was found that the median
value for the lower limit of benefit was 20 % absolute risk
reduction over 5 years [31]. This is an interesting outcome as it
could mean that, if also applicable to our patients, even in our
case with an assumed (relatively high) relative risk reduc-
tion of 50 % with these drugs, for many patients, their
expectation of benefit will be higher than the actual ben-
efit provided by the drug. Possibly, the fact sheet, if fully
applicable and presented at the right moment, may have
the potential to increase adherence rates and to reduce
discontinuation rates by offering patients the opportunity
to choose a drug that fits to their daily life or to exchange
one drug for another if it turns out that their first choice
was not what they thought about it.
In conclusion, this study reports the development a PET to
assist postmenopausal women with osteoporosis in selecting a
treatment that is in line with their personal values and prefer-
ences. All patients interviewed during alpha testing expressed
a positive attitude towards the use of a PET. Further develop-
ment of the PET including the fact sheet, field testing, and
research of their effects on patient outcomes will be next im-
portant steps.
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